cervical cancer

Nykode collaborates with Roche for an upcoming trial in cervical cancer
Nykode collaborates with Roche for an upcoming trial in cervical cancer
Clinical Trials Arena
Nykode Therapeutics
Roche
cervical cancer
VB10.16
clinical trials
Flag link:
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
ASCO: Merck gives final look at Keytruda study in first-line cervical cancer. Will FDA change its mind?
Fierce Pharma
ASCO 2023
Merck
Keytruda
cervical cancer
Flag link:
Nykode vaccine shows its worth in cervical cancer trial
Nykode vaccine shows its worth in cervical cancer trial
Pharmaforum
Nykode Therapeutics
vaccines
cervical cancer
VB10.16
Flag link:
AstraZeneca's Imfinzi Fails to Boost Survival in Cervical Cancer
AstraZeneca's Imfinzi Fails to Boost Survival in Cervical Cancer
BioSpace
AstraZeneca
Imfinizi
cervical cancer
clinical trials
Flag link:
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
Flag link:
Immuno-oncology spotlight falls on cervical cancer
Immuno-oncology spotlight falls on cervical cancer
EP Vantage
immuno-oncology
cervical cancer
Opdivo
Keytruda
Bristol Myers Squibb
Merck
Flag link:
HPV vaccines reduce cervical cancer by 87%: study
HPV vaccines reduce cervical cancer by 87%: study
Biopharma Reporter
HPV
vaccines
cervical cancer
RWE
Flag link:
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Fierce Biotech
Agenus
cervical cancer
balstilimab
Merck
Flag link:
Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut
Merck carves out path in first-line advanced cervical cancer with new FDA win for Keytruda juggernaut
Endpoints
Merck
Keytruda
FDA
cervical cancer
Flag link:
Regeneron Could Have a Big Catalyst Coming in 2022
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Regeneron
Libtayo
cervical cancer
FDA
Sanofi
Flag link:
FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising
FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising
Endpoints
Seagen
Genmab
Tivdak
FDA
accelerated approval
cervical cancer
Flag link:
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
Flag link:
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Fierce Biotech
Agenus
FDA
balstilimab
cervical cancer
clinical trials
Flag link:
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Merck's Keytruda extends life for cervical cancer patients in first-in-class win
Fierce Pharma
Merck
Keytruda
cervical cancer
clinical trials
Flag link:
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Sanofi, Regeneron’s Libtayo improves survival in cervical cancer patients
Pharma Times
Sanofi
Regeneron
Libtayo
cervical cancer
clinical trials
Flag link:
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
Seattle Genetics/Genmab's tisotumab’s cervical cancer efficacy falls off
EP Vantage
cervical cancer
tisotumab vedotin
Genmab
Seattle Genetics
clinical trials
Flag link:
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
EP Vantage
Genmab
tisotumab vedotin
cervical cancer
Zogenix
Fintepla
Lennox-Gastaut Syndrome
Flag link:
Just One HPV Dose May Be Enough To Prevent Several Cancers
Just One HPV Dose May Be Enough To Prevent Several Cancers
Forbes
vaccines
HPV
Merck
Gardasil
cervical cancer
Flag link:
Emboldened by ASCO data, FDA etches speedy approval path for Iovance's cervical cancer therapy
Emboldened by ASCO data, FDA etches speedy approval path for Iovance's cervical cancer therapy
Endpoints
FDA
cervical cancer
Iovance
LN-145
Flag link:
Genmab files for $500M IPO to fund multi-front cancer R&D push
Genmab files for $500M IPO to fund multi-front cancer R&D push
Fierce Biotech
Genmab
IPOs
antibody-drug conjugate
cervical cancer
Flag link:

Pages